Increased Expression of CD44 Variants in Differentiated Thyroid Cancers

Takano, Toru; Sumizaki, Hiromi; Nakano, Kouichi; Matsuzuka, Fumio; Kuma, Kanji; Amino, Nobuyuki

doi:10.1111/j.1349-7006.1996.tb03139.x

Cited by 12 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that a specific CD44 splice variant, CD44v8-10, which contains variant exons 8, 9, and 10 (also referred to as CD44R1) is highly expressed in colon carcinomas compared with adjacent nonneoplastic tissues (44). Since we reported this finding, other groups have also described the predominant expression of CD44v8-10 in various human carcinomas, including breast (34), gastric (41), and thyroid (45). To analyze CD44v8-10 expression further, in this study we examined the CD44 splice variants expressed in non-small-cell lung carcinomas (NSCLCs) and bladder carcinomas and confirmed that CD44v8-10 was the most dominant splice variant in these tumor tissues.…”

supporting

confidence: 63%

Molecular Detection of Cancer Cells by Competitive Reverse Transcription-Polymerase Chain Reaction Analysis of Specific CD44 Variant RNAs

Okamoto¹,

Morisaki²,

Sasaki³

et al. 1998

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

show abstract

supporting

confidence: 63%

Molecular Detection of Cancer Cells by Competitive Reverse Transcription-Polymerase Chain Reaction Analysis of Specific CD44 Variant RNAs

Okamoto¹,

Morisaki²,

Sasaki³

et al. 1998

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

show abstract

“…Among the overexpressed genes, many are known from previous studies to be involved in PTC. A prototype example is FN1 (fibronectin 1), which is highly overexpressed in PTC (11). Other examples include MET (12), DPP4 (dipeptidylpeptidase IV) (13), SER-PINA1 (␣ 1-antitrypsin) (14), KRT19 (keratin 19) (15), and LGALS3 (galectin-3) (16), which were overexpressed in all eight PTC samples.…”

Section: Resultsmentioning

confidence: 99%

Gene expression in papillary thyroid carcinoma reveals highly consistent profiles

Huang

Prasad

Lemon

et al. 2001

Proc. Natl. Acad. Sci. U.S.A.

394

298

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is clinically heterogeneous. Apart from an association with ionizing radiation, the etiology and molecular biology of PTC is poorly understood. We used oligobased DNA arrays to study the expression profiles of eight matched pairs of normal thyroid and PTC tissues. Additional PTC tumors and other tissues were studied by reverse transcriptase-PCR and immunohistochemistry. The PTCs showed concordant expression of many genes and distinct clustered profiles. Genes with increased expression in PTC included many encoding adhesion and extracellular matrix proteins. Expression was increased in 8͞8 tumors for 24 genes and in 7͞8 tumors for 22 genes. Among these genes were several previously known to be overexpressed in PTC, such as MET, LGALS3, KRT19, DPP4, MDK, TIMP1, and FN1. The numerous additional genes include CITED1, CHI3L1, ODZ1, N33, SFTPB, and SCEL. Reverse transcriptase-PCR showed high expression of CITED1, CHI3L1, ODZ1, and SCEL in 6͞6 additional PTCs. Immunohistochemical analysis detected CITED1 and SFTPB in 49͞52 and 39͞52 PTCs, respectively, but not in follicular thyroid carcinoma and normal thyroid tissue. Genes underexpressed in PTC included tumor suppressors, thyroid function-related proteins, and fatty acid binding proteins. Expression was decreased in 7͞8 tumors for eight genes and decreased in 6͞8 tumors for 19 genes. We conclude that, despite its clinical heterogeneity, PTC is characterized by consistent and specific molecular changes. These findings reveal clues to the molecular pathways involved in PTC and may provide biomarkers for clinical use.

show abstract

“…The study also showed increased expression of CD44 variants compared with normal thyroid tissues in FTC, PTC, and some follicular adenomas 52. It is believed that the expression of CD44v3 and CD44v6 variant isoforms might be crucial in the development of nodal metastasis in cases of FTC 53.…”

Section: The Biomarkers For Tmn Oncolytic Virotherapymentioning

confidence: 65%

“… 51 The study also showed increased expression of CD44 variants compared with normal thyroid tissues in FTC, PTC, and some follicular adenomas. 52 It is believed that the expression of CD44v3 and CD44v6 variant isoforms might be crucial in the development of nodal metastasis in cases of FTC. 53 CD44 was detected with an antibody recognizing all forms of CD44, including CD44v3 and CD44v6 variant isoforms, in 213 patients with DTC.…”

Section: The Biomarkers For Tmn Oncolytic Virotherapymentioning

confidence: 99%

Thyroid malignancy neoplasm-associated biomarkers as targets for oncolytic virotherapy

Guan

Shah

et al. 2016

View full text Add to dashboard Cite

Biomarkers associated with thyroid malignant neoplasm (TMN) have been widely applied in clinical diagnosis and in research oncological programs. The identification of novel TMN biomarkers has greatly improved the efficacy of clinical diagnosis. A more accurate diagnosis may lead to better clinical outcomes and effective treatments. However, the major deficiency of conventional chemotherapy and radiotherapy is lack of specificity. Due to the macrokinetic interactions, adverse side effects will occur, including chemotherapy and radiotherapy resistance. Therefore, a new treatment is urgently needed. As an alternative approach, oncolytic virotherapy may represent an opportunity for treatment strategies that can more specifically target tumor cells. In most cases, viral entry requires the expression of specific receptors on the surface of the host cell. Currently, molecular virologists and gene therapists are working on engineering oncolytic viruses with altered tropism for the specific targeting of malignant cells. This review focuses on the strategy of biomarkers for the production of novel TMN oncolytic therapeutics, which may improve the specificity of targeting of tumor cells and limit adverse effects in patients.

show abstract

Increased Expression of CD44 Variants in Differentiated Thyroid Cancers

Cited by 12 publications

References 16 publications

Molecular Detection of Cancer Cells by Competitive Reverse Transcription-Polymerase Chain Reaction Analysis of Specific CD44 Variant RNAs

Molecular Detection of Cancer Cells by Competitive Reverse Transcription-Polymerase Chain Reaction Analysis of Specific CD44 Variant RNAs

Gene expression in papillary thyroid carcinoma reveals highly consistent profiles

Thyroid malignancy neoplasm-associated biomarkers as targets for oncolytic virotherapy

Contact Info

Product

Resources

About